ESN Cleer
- Company typePrivate
- Founded2018
- HeadquartersMelbourne, Australia
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
ESN Cleer firmographics
Firmographics- Name
- ESN Cleer
- Legal name
- Endothelium Scanning Nanotechnology Ltd.
- Website
- https://cleer.com.au
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
ESN Cleer industry classification
Industry- Product category
- Orphan Cardiomyopathy Biopharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG)
- akta.pro secondary industry
- Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)
Keywords
Where ESN Cleer is headquartered
LocationHeadquarters
- HQ city
- Melbourne
- HQ country
- Australia
- HQ region
- Oceania
Offices1 record
Markets served
ESN Cleer business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Drug Development and Commercialisation: Pre-revenue biotech company developing repurposed drugs for orphan indications. Anticipated licensing and M&A opportunities to support growth. Revenue expected through drug commercialisation upon regulatory approval.
- Orphan Drug Commercialisation: Targeting orphan drug market projected to reach US$300b reaching 20% of all drug sales by 2028. US Government's Orphan Drug Act provides substantial incentives including Medicare and Medicaid coverage.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
ESN Cleer product offering
Product offeringCore offering
ESN Cleer is a pre-revenue biopharmaceutical company developing repurposed drugs for orphan indications in cardiomyopathies. Its lead product, ESNtx005, is a proprietary repurposed drug with novel composition of matter targeting specific rare disease subgroups within the cardiomyopathy market segment, using a precision medicine approach to accelerate clinical development. The company intends to commercialise through licensing deals and M&A with pharmaceutical partners.
Product overview
ESN Cleer is a precision therapeutics company developing repurposed drugs for orphan indications in cardiomyopathies. Its primary product is ESNtx005, a repurposed drug targeting rare disease subgroups within the cardiomyopathy market segment. The company leverages a de-risked development approach with regulatory advantages through orphan drug pathways.
Differentiator
Problem solved
Functional benefit
Brands
- ESNtx005: Repurposed drug developed by ESN Cleer targeted to specific rare disease subgroups within the Cardiomyopathy market segment, featuring novel composition of matter and precision medicine approach.
Products and services
- ESNtx005
Quantifiable outcome
- Significant reduction in development cost, time and risks compared to traditional drug development
Companies that use ESN Cleer
Customer profileSegments1 record
Ideal customer profiles2 records
ESN Cleer technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
ESN Cleer partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Alira HealthcoreIndependent renowned global healthcare and life sciences sector services provider. ESN's regulatory and market access is at 70% Optimising phase, well-advanced towards commercialisation.
- ElioncoreIndependent Intellectual Property legal powerhouse for biotech and Medtech industry. ESN's IP protection (market access/exclusivity/value) is at an astounding 80% rating.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
ESN Cleer competitors and assessment
Company assessmentDirect peers
- BridgeBio Pharma: Clinical-stage rare-disease biotech with a leading cardiomyopathy program (acoramidis for ATTR-CM). Highly comparable to ESN Cleer as a rare/precision cardiovascular company pursuing orphan cardiac indications.
- Cytokinetics: Cardiovascular-focused biotech developing cardiac myosin modulators for heart failure and cardiomyopathies. Comparable target indication (heart failure with preserved/mid-range ejection fraction and HCM) and orphan cardiovascular commercial thesis.
- Stealth BioTherapeutics: Clinical-stage company developing elamipretide for rare mitochondrial cardiomyopathies including Barth syndrome. Directly comparable as an orphan/rare cardiomyopathy drug developer.
Emerging players
- Tenaya Therapeutics: Genetic medicines company developing therapies for cardiomyopathies and rare cardiac diseases. Comparable rare cardiomyopathy focus with a precision-medicine approach to genetic heart disease.
- Lexeo Therapeutics: Clinical-stage gene therapy company with cardiomyopathy programs (e.g., Friedreich's ataxia cardiomyopathy). Comparable rare cardiac disease focus and small-cap clinical biotech profile.
- Cardior Pharmaceuticals: European clinical-stage biotech developing RNA-based therapeutics for heart failure and cardiac remodeling. Comparable in size, stage, and orphan/precision cardiovascular therapeutic positioning.
- Imbria Pharmaceuticals: Clinical-stage biotech developing novel cardiometabolic therapies for heart failure with preserved ejection fraction. Comparable orphan/precision cardiology positioning.
- Rocket Pharmaceuticals: Late-stage gene therapy company with cardiac programs targeting rare inherited cardiomyopathies (e.g., Danon disease). Comparable rare cardiac disease focus and small-cap clinical biotech status.
Broad incumbents
- Novartis (Entresto franchise): Global pharmaceutical company with a dominant heart failure franchise (Entresto/sacubitril-valsartan). Comparable as the incumbent standard-of-care in heart failure that ESNtx005's orphan subgroups would be measured against.
- Alnylam Pharmaceuticals: Established orphan-disease RNA therapeutics company with a commercial cardiomyopathy asset (Onpattro/Amvuttra-related, and patisiran/Amvuttra in ATTR-CM). Comparable as a successful orphan-cardiology commercial benchmark.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
ESN Cleer social profiles
Digital presenceESN Cleer financial estimates
Financial estimateRevenue estimate
Valuation estimate
ESN Cleer leadership team
Management profileNumber of profiles
Profiles11 records
ESN Cleer funding detail
Funding detailFunding overview
Funding rounds6 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ESN Cleer M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ESN Cleer
What does ESN Cleer do?
ESN Cleer is a pre-revenue biopharmaceutical company developing repurposed drugs for orphan indications in cardiomyopathies. Its lead product, ESNtx005, is a proprietary repurposed drug with novel composition of matter targeting specific rare disease subgroups within the cardiomyopathy market segment, using a precision medicine approach to accelerate clinical development. The company intends to commercialise through licensing deals and M&A with pharmaceutical partners.
Is ESN Cleer a public or private company?
ESN Cleer is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was ESN Cleer founded?
ESN Cleer was founded in 2018. It employs 1 to 10 people.
Where is ESN Cleer based?
ESN Cleer is headquartered in Melbourne, Australia, in the Oceania region.
How does ESN Cleer make money?
Two revenue lines are on record. Drug Development and Commercialisation is the primary driver. The others are orphan Drug Commercialisation.
Who are ESN Cleer's main competitors?
Direct peers on record are BridgeBio Pharma, Cytokinetics and Stealth BioTherapeutics. Emerging players are Tenaya Therapeutics, Lexeo Therapeutics, Cardior Pharmaceuticals, Imbria Pharmaceuticals and Rocket Pharmaceuticals. Broad incumbents are Novartis (Entresto franchise) and Alnylam Pharmaceuticals.
Does ESN Cleer have an API?
No public API is recorded for ESN Cleer.
What industry is ESN Cleer in?
ESN Cleer's product category is Orphan Cardiomyopathy Biopharmaceuticals. Its primary akta.pro industry code is HLAIACAG, Cardiology & Vascular Specialty Pharmaceuticals, with a secondary code of HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 325412 and its SIC code is 2834.